Showing 1–16 of 20 results
-
Sale!
Adakveo (crizanlizumab)
$1,999.00Adakveo (crizanlizumab) is a medication used to prevent painful crises in patients with sickle cell disease aged 16 years and older.
It is the first targeted therapy approved for sickle cell disease.
-
Sale!
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
$29,999.004 vials
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a medication used for the treatment of patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
This is the first approved antidote for apixaban- or rivaroxaban-treated patients with uncontrolled bleeds.
-
Sale!
Besremi (ropeginterferon alfa-2b)
$1,299.00 – $4,599.00Besremi (ropeginterferon alfa-2b) is a medication used to treat Polycythaemia Vera (PV) in adult patients.
-
Bylvay (odevixibat)
Bylvay (odevixibat) is a prescription medicine used to treat pruritus in patients aged 3 months and older, with progressive familial intrahepatic cholestasis (PFIC).
-
Sale!
Cablivi
$4,587.67Cablivi (caplacizumab) is a medicine approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP). It is available in powder form or solution for injection, to be used in combination with plasma exchange and immunosuppressive therapy.
-
Sale!
Enjaymo (sutimlimab)
$1,200.00Enjaymo (sutimlimab) is a medication used to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
-
Sale!
Evrenzo (roxadustat)
$120.00 – $950.45Evrenzo (roxadustat) is a medication used for the treatment of anemia associated with chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
-
Sale!
Feraccru (ferric maltol)
$100.00Feraccru (ferric maltol) is a medication used for the treatment of iron deficiency with or without anemia in adults.
Feraccru (ferric maltol) was approved by the EMA in May 2019 under the trade name Accrufer (ferric maltol). It is available to order as well. See Accrufer (ferric maltol).
-
Sale!
Givlaari (givosiran)
$52,362.00Givlaari (givosiran) is a medication used for the treatment of adult patients and children aged 12 years and older with acute hepatic porphyria.
-
Sale!
Inrebic (fedratinib)
$5,500.00Inrebic (fedratinib) is a medication used for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
-
Korsuva (difelikefalin)
Korsuva (difelikefalin) is a medication used to treat moderate-to-severe pruritus (itch) in patients on hemodialysis (HD).
-
Sale!
Livmarli (maralixibat)
$1,200.00Livmarli (maralixibat) is an oral solution to treat cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.
-
Sale!
Mircera (methoxy polyethylene glycol-epoetin beta)
$80.00 – $949.94Mircera (methoxy polyethylene glycol-epoetin beta) is a prescription medicine used for the treatment of anemia associated with chronic kidney disease (CKD).
-
Sale!
Ondexxya (andexanet alfa)
$20,500.004 vials
Ondexxya (andexanet alfa) is a medication used for the treatment of patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
This is the first approved antidote for apixaban- or rivaroxaban-treated patients with uncontrolled bleeds.
Ondexxya (andexanet alfa) was approved by the FDA in May 2018 under the trade name Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). It is available to order as well. See Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo).
-
Sale!
Oxbryta (voxelotor)
$41,100.00Oxbryta (voxelotor) is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and children 12 years of age and older.
-
Sale!
Reblozyl (luspatercept)
$1,999.00Reblozyl (luspatercept) is a medication used for the treatment of adults with anemia (low red blood cells) associated with beta thalassemia or myelodysplastic syndromes.
